DeepMed Research

BEYOND AIR INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors

Phase 1

Recruiting

Conditions: Cancer

Interventions: Drug: Nitric Oxide 50,000 ppm
Drug: Nitric Oxide 100,000 ppm
Drug: Nitric Oxide selected dose
Drug: Nitric Oxide 25,000 ppm

First Posted Date: 2022-04-28

Last Posted Date: 2024-08-16

Lead Sponsor: Beyond Air Inc.

Target Recruit Count: 38

Registration Number: NCT05351502

Locations: 🇮🇱
Soroka Medical Center, Be'er Sheva, Israel
🇮🇱
Sheba Medical Center, Ramat Ef'al, Israel
🇮🇱
Hadassah Ein-Karem, Jerusalem, Israel

and more 1 locations

A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients

Not Applicable

Completed

Conditions: Cystic Fibrosis
Mycobacterial Pneumonia
Mycobacterium Avium Complex
Mycobacterium Abscessus Infection
Non-Tuberculous Mycobacterial Pneumonia

Interventions: Device: LungFit

First Posted Date: 2020-12-28

Last Posted Date: 2022-12-16

Lead Sponsor: Beyond Air Inc.

Target Recruit Count: 15

Registration Number: NCT04685720

Locations: 🇦🇺
Gallipoli Medical Research Foundation, Greenslopes, Queensland, Australia

Inhaled NO for the Treatment of Viral Pneumonia in Adults

Not Applicable

Completed

Conditions: Covid19
Respiratory Disease
Pneumonia, Viral
Viral Pneumonia
Nitric Oxide
Inhaled Nitric Oxide
SARS-CoV Infection

Interventions: Device: LungFit™

First Posted Date: 2020-10-28

Last Posted Date: 2022-12-16

Lead Sponsor: Beyond Air Inc.

Target Recruit Count: 40

Registration Number: NCT04606407

Locations: 🇮🇱
Hasharon Medical Center, Petah Tikva, Israel
🇮🇱
Rabin Medical Center, Petah Tikva, Israel
🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)

Phase 2

Withdrawn

Conditions: SARS-CoV 2
Corona Virus Infection
COVID-19
Pneumonia, Viral
Respiratory Disease

Interventions: Combination Product: 150 ppm Nitric Oxide delivered through LungFit Delivery System
Combination Product: 80 ppm Nitric Oxide delivered through LungFit Delivery System

First Posted Date: 2020-07-02

Last Posted Date: 2021-01-22

Lead Sponsor: Beyond Air Inc.

Registration Number: NCT04456088

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

Not Applicable

Terminated

Conditions: COVID-19
SARS-CoV 2
Respiratory Disease
Inhaled Nitric Oxide
Nitric Oxide
Pneumonia, Viral
Corona Virus Infection

Interventions: Device: Nitric Oxide delivered via LungFit™ system

First Posted Date: 2020-05-21

Last Posted Date: 2022-12-16

Lead Sponsor: Beyond Air Inc.

Target Recruit Count: 4

Registration Number: NCT04397692

Locations: 🇺🇸
Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States

Evaluation of Two Doses of Nitric Oxide (NO) Given Intermittently Via Inhalation to Subjects With Bronchiolitis

Phase 2

Completed

Conditions: Bronchiolitis Acute

Interventions: Other: Standard Supportive treatment
Drug: Nitric Oxide

First Posted Date: 2019-08-19

Last Posted Date: 2020-05-12

Lead Sponsor: Beyond Air Inc.

Target Recruit Count: 95

Registration Number: NCT04060979

Locations: 🇮🇱
Haemek Medical Center, Afula, Israel
🇮🇱
Soroka Medical Center, Be'er Sheva, Israel
🇮🇱
Assuta Ashdod, Ashdod, Israel

and more 4 locations

Inhaled Nitric Oxide for Patients With MABSC

Phase 2

Completed

Conditions: Mycobacterium Abscessus Infection

Interventions: Drug: Nitric Oxide

First Posted Date: 2017-07-06

Last Posted Date: 2019-07-09

Lead Sponsor: Beyond Air Inc.

Target Recruit Count: 9

Registration Number: NCT03208764

Locations: 🇮🇱
Rambam Medical Center, Haifa, Israel

Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis

Phase 3

Completed

Conditions: Bronchiolitis

Interventions: Drug: Nitric Oxide
Other: Supportive treatment

First Posted Date: 2017-02-15

Last Posted Date: 2019-07-09

Lead Sponsor: Beyond Air Inc.

Target Recruit Count: 69

Registration Number: NCT03053388

Locations: 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
🇮🇱
Barzili Medical Center, Ashkelon, Israel
🇮🇱
Carmel Medical Center, Haifa, Israel

and more 7 locations

Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Nitric oxide

First Posted Date: 2013-10-09

Last Posted Date: 2016-06-03

Lead Sponsor: Beyond Air Inc.

Target Recruit Count: 9

Registration Number: NCT01958944

Locations: 🇮🇱
Soroka university, Beer-Sheba, Israel
🇮🇱
Schneider Children's Medical Center of Israel, Petach Tikvah, Israel

Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With Bronchiolitis

Phase 1

Completed

Conditions: Bronchiolitis

Interventions: Drug: Placebo
Drug: Nitric Oxide

First Posted Date: 2013-01-16

Last Posted Date: 2016-05-04

Lead Sponsor: Beyond Air Inc.

Target Recruit Count: 43

Registration Number: NCT01768884

Locations: 🇮🇱
Soroka university, Beer-Sheba, Israel

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy